H. Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
H. Tran has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
H. H. Salem
Clinical Haematology Department, Alfred Hospital and
1 shared publicationM. Collecutt
Alfred Pathology Service
1 shared publicationS. Whitehead
Alfred Pathology Service
1 shared publication
Latest Publications
- 20 April 2011
- Published by Wiley in Internal Medicine Journal
- Vol. 41 (4) , 337-343
Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation
Background: Prothrombinex‐VF (a three‐factor prothrombin complex concentrate) contains little factor VII. Therefore, the Warfarin Reversal Consensus Guidelines from 2004 published by The Australasian Society of Haemostasis and Thrombosis recommend that it be administered with fresh frozen plasma to reverse warfarin anticoagulation.Aim: To evaluate the efficacy and safety of Prothrombinex‐VF used alone in warfarin reversal.Methods: Adult patients requiring urgent reversal of warfarin anticoagulation were defined as having achieved complete (target international normalized ratio (INR) Results: A total of 50 patients (mean age 72 years, range 32–85 years) was included. The median initial INR in the complete reversal arm (n= 35) was 3.5 (range 1.7–20) with 91% achieving the target INR (mean 1.1, range 0.9–1.4). In the partial reversal arm (n= 15) the mean initial INR was 5.6 (range 2.5–12) with 93% achieving the target INR (mean 1.6, range 1.4–2.2). There were no adverse effects attributed to Prothrombinex‐VF.Conclusions: Prothrombinex‐VF is very effective and safe when used alone to reverse warfarin anticoagulation. The supplementary use of fresh frozen plasma in these patients is not required. A review of the current Warfarin Reversal Consensus Guidelines is needed.
- 20 April 2011
- Published by Wiley in Internal Medicine Journal
- Vol. 41 (4) , 337-343
Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation
Background: Prothrombinex‐VF (a three‐factor prothrombin complex concentrate) contains little factor VII. Therefore, the Warfarin Reversal Consensus Guidelines from 2004 published by The Australasian Society of Haemostasis and Thrombosis recommend that it be administered with fresh frozen plasma to reverse warfarin anticoagulation.Aim: To evaluate the efficacy and safety of Prothrombinex‐VF used alone in warfarin reversal.Methods: Adult patients requiring urgent reversal of warfarin anticoagulation were defined as having achieved complete (target international normalized ratio (INR) Results: A total of 50 patients (mean age 72 years, range 32–85 years) was included. The median initial INR in the complete reversal arm (n= 35) was 3.5 (range 1.7–20) with 91% achieving the target INR (mean 1.1, range 0.9–1.4). In the partial reversal arm (n= 15) the mean initial INR was 5.6 (range 2.5–12) with 93% achieving the target INR (mean 1.6, range 1.4–2.2). There were no adverse effects attributed to Prothrombinex‐VF.Conclusions: Prothrombinex‐VF is very effective and safe when used alone to reverse warfarin anticoagulation. The supplementary use of fresh frozen plasma in these patients is not required. A review of the current Warfarin Reversal Consensus Guidelines is needed.